Loading...

SANA SANA BIOTECHNOLOGY INC Business Restructuring 8-K Filing

SN B

SN

SANA BIOTECHNOLOGY INC

(SANA)

2023 8-K

Show Summary

Summary

Product Expansion

Equity Offerings

Financial Results

Corporate Presentation

Financial Results

Management Changes

Management Change

Earnings Reports

Annual Meeting Results

Financial Results Announcement

Resignation of Executive

Financial Results Announcement

Public Offering

Financial Update

Conference Presentation

Financial Results Announcement

Portfolio Update and Workfo...

Regulation FD Disclosure

Termination of Lease Agreement

Financial Results Announcement

Annual Meeting Results

Presentation at Conference

Earnings Reports

Resignation of Executive

Management Changes

Financial Results Announcement

FDA Clearance for First-in-...

FDA Clearance for First-in-...

Regulation FD Disclosure

External Links:

Sana Biotechnology plans to focus on ex vivo cell therapy and reduce investment in in vivo gene delivery, resulting in a workforce reduction of 29% and expected operating cash burn of less than $200 million in 2024.

AI Assistant

SANA BIOTECHNOLOGY INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.